LG Energy Solution Shares Slide After Ford Cancels EV Battery Supply Deal 
FedEx Beats Q2 Earnings Expectations, Raises Full-Year Outlook Despite Stock Dip 
Toyota to Sell U.S.-Made Camry, Highlander, and Tundra in Japan From 2026 to Ease Trade Tensions 
Union-Aligned Investors Question Amazon, Walmart and Alphabet on Trump Immigration Policies 
OpenAI Explores Massive Funding Round at $750 Billion Valuation 
Micron Technology Forecasts Surge in Revenue and Earnings on AI-Driven Memory Demand 
ANZ New CEO Forgoes Bonus After Shareholders Reject Executive Pay Report 
Trump Administration Reviews Nvidia H200 Chip Sales to China, Marking Major Shift in U.S. AI Export Policy 
Delta Air Lines President Glen Hauenstein to Retire, Leaving Legacy of Premium Strategy 
Harris Associates Open to Revised Paramount Skydance Bid for Warner Bros Discovery 
Apple Explores India for iPhone Chip Assembly as Manufacturing Push Accelerates 
Treasury Wine Estates Shares Plunge on Earnings Warning Amid U.S. and China Weakness 
Shell M&A Chief Exits After BP Takeover Proposal Rejected 
Amazon in Talks to Invest $10 Billion in OpenAI as AI Firm Eyes $1 Trillion IPO Valuation 
Sanofi’s Efdoralprin Alfa Gains EMA Orphan Status for Rare Lung Disease 
Blackstone Leads $400 Million Funding Round in Cyera at $9 Billion Valuation 
Maersk Vessel Successfully Transits Red Sea After Nearly Two Years Amid Ongoing Security Concerns 
CAMBRIDGE, Mass., Sept. 23, 2016 -- Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, today announced the appointment of Corey N. Fishman to its Board of Directors effective September 22, 2016. Mr. Fishman currently serves as Chief Executive Officer of Iterum Therapeutics Limited, a clinical-stage pharmaceutical company developing differentiated anti-infectives for combatting multi-drug resistant pathogens.
“We are very pleased to welcome Corey to Momenta’s Board of Directors at this important stage in our company’s development and growth,” said Craig Wheeler, President and CEO, Momenta Pharmaceuticals. “Corey is a seasoned pharmaceutical industry executive with a unique combination of commercial, operations, finance and business development expertise. His extensive experience will be a great asset to our Company as we continue to advance our pipeline of complex generic, biosimilar and novel drug candidates toward commercialization.”
Mr. Fishman has served as Chief Executive Officer of Iterum Therapeutics Limited since its founding in late 2015. Previously he served as Chief Financial and Chief Operating Officer of Durata Therapeutics, Inc. where he managed a successful IPO and secondary offering, and led the negotiation and sale of the Company to Actavis plc. Prior to Durata, Mr. Fishman served as Chief Financial Officer of Ganic Pharmaceuticals, Inc., a Warburg Pincus Company, and served in several leadership roles, including Chief Financial Officer, at MedPointe Healthcare, Inc. Mr. Fishman holds a BA in Economics from the University of Illinois at Urbana-Champaign and an MSM in Finance from the Krannert School of Management at Purdue University.
About Momenta
Momenta Pharmaceuticals is a biotechnology company specializing in the detailed structural analysis of complex drugs and is headquartered in Cambridge, MA. Momenta is applying its technology to the development of generic versions of complex drugs, biosimilar and potentially interchangeable biologics, and to the discovery and development of novel therapeutics for autoimmune indications.
To receive additional information about Momenta, please visit the website at www.momentapharma.com, which does not form a part of this press release.
Our logo, trademarks, and service marks are the property of Momenta Pharmaceuticals, Inc. All other trade names, trademarks, or service marks are property of their respective owners.
Forward Looking Statements
Statements in this press release regarding management's future expectations, beliefs, intentions, goals, strategies, plans or prospects, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including but not limited to statements about Mr. Fishman benefitting the Company; advancing our product pipeline; and bringing multiple products to market in the coming years. Forward-looking statements may be identified by words such as "continue," "will" and other similar words or expressions, or the negative of these words or similar words or expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors, including those referred to under the section "Risk Factors" in the Company's Quarterly Report on Form 10-Q for the month ended June 30, 2016, filed with the Securities and Exchange Commission, as well as other documents that may be filed by the Company from time to time with the Securities and Exchange Commission. As a result of such risks, uncertainties and factors, the Company's actual results may differ materially from any future results, performance or achievements discussed in or implied by the forward-looking statements contained herein. The Company is providing the information in this press release as of this date and assumes no obligations to update the information included in this press release or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
INVESTOR CONTACT: Sarah Carmody Momenta Pharmaceuticals 1-617-395-5189 [email protected] MEDIA CONTACT: Karen Sharma MacDougall Biomedical Communications 1-781-235-3060 [email protected]
